The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Qu, Qing ^a   Zong, Yu ^a   Fei, Xiao chun ^a   Chen, Xiao song ^a   Xu, Cheng ^a   Lou, Gu yin ^a   Shen, Kun wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biopsy; Breast cancer; Metastasis; Receptor status; Second malignancy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ABDOMINAL CANCER; ADULT; AGED; ARTICLE; BONE CANCER; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LUNG CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDIASTINUM CANCER; PANCREAS CANCER; PELVIS CANCER; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SECOND CANCER; THORAX WALL CANCER; TUMOR BIOPSY;

ADULT; AGED; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, MAMMARY;

EID: 84899125586     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-93     Document Type: Article

References (36)

1. Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, Gao YT, Zheng W, Colditz GA. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst 2008, 100:1352-1360. 10.1093/jnci/djn305, 2556703, 18812552.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792. 10.1056/NEJMoa050518, 16251534.
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
7. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol 2010, 4:404-419. 10.1016/j.molonc.2010.06.005, 3023958, 20599450.
8. Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. Lancet Oncol 2009, 10:933-935. 10.1016/S1470-2045(09)70295-5, 19796747.
9. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005, 23:2469-2476. 10.1200/JCO.2005.01.172, 15753463.
10. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995, 55:3331-3338.
11. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504. 10.1093/annonc/mdp028, 2731014, 19299408.
12. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996, 14:2584-2589.
13. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D. Comparison of HER2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002, 13:1036-1043. 10.1093/annonc/mdf252, 12176781.
14. Hao XS, Chen KS, Liu H. Analysis of female breast cancer descriptive epidemiology in Tianjin, China. Asian Pac J Cancer Prev 2002, 3:143-148.
15. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ. Changes in estrogen receptor, progesterone receptor and HER2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009, 29:1557-1562.
16. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93:552-556. 10.1038/sj.bjc.6602738, 2361603, 16106267.
17. Jensen JD, Knoop A, Ewertz M, Laenkholm AV. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat 2012, 132:511-521. 10.1007/s10549-011-1610-3, 21667123.
18. Liu J, Deng H, Jia W, Zeng Y, Rao N, Li S, Jin L, Wu J, Song E, Su F. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment. J Cancer Res Clin Oncol 2012, 138:837-842.
19. Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012, 30:2601-2608. 10.1200/JCO.2011.37.2482, 22711854.
20. Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van Gils CH, van der Wall E, van Diest PJ. Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012, 118:4929-4935. 10.1002/cncr.27518, 22415862.
21. Gong Y, Booser DJ, Sneige N. Comparison of HER2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103:1763-1769. 10.1002/cncr.20987, 15786420.
22. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20:1953-1958. 10.1093/annonc/mdp263, 2791352, 19596702.
23. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010, 12:R92. 10.1186/bcr2771, 3046433, 21059212.
24. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895. 10.1126/science.887927, 887927.
25. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572. 10.1038/nrc865, 12154349.
26. Hawkins RA, Tesdale AL, Anderson ED, Levack PA, Chetty U, Forrest AP. Does the oestrogen receptor concentration of a breast cancer change during systemic therapy?. Br J Cancer 1990, 61:877-880. 10.1038/bjc.1990.196, 1971691, 2372489.
27. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010, 15:1164-1168. 10.1634/theoncologist.2010-0059, 3227913, 21041379.
28. Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J. When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann Oncol 2012, 23(Suppl 10):x349-x353. 10.1093/annonc/mds297, 22987990.
29. Brown LM, Chen BE, Pfeiffer RM, Schairer C, Hall P, Storm H, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fosså SD, Travis LB. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007, 106:439-451. 10.1007/s10549-007-9509-8, 17277968.
30. Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 2008, 98:870-874. 10.1038/sj.bjc.6604241, 2266852, 18268495.
31. Shilkrut M, Belkacemi Y, Kuten A. Secondary malignancies in survivors of breast cancer: how to overcome the risk. Crit Rev Oncol Hematol 2012, 84(Suppl 1):e86-e89.
32. Vidal-Millan S, Zeichner-Gancz I, Flores-Estrada D, Vela-Rodriguez BE, Vazquez-Lopez MI, Robles-Vidal CD, Ramirez-Ugalde MT, Chavez-MacGregor M. A descriptive study of second primary malignancies associated to breast cancer in a Mexican Hispanic population. Med Oncol 2005, 22:17-22. 10.1385/MO:22:1:017, 15750192.
33. Rena O, Papalia E, Ruffini E, Filosso PL, Oliaro A, Maggi G, Casadio C. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol 2007, 33:546-550. 10.1016/j.ejso.2006.12.015, 17267164.
34. Lee KD, Chen SC, Chan CH, Lu CH, Chen CC, Lin JT, Chen MF, Huang SH, Yeh CM, Chen MC. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev 2008, 17:2647-2655. 10.1158/1055-9965.EPI-08-0109, 18843006.
35. Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM. Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat 2007, 105:195-207. 10.1007/s10549-006-9446-y, 17186360.
36. Prochazka M, Hall P, Granath F, Czene K. Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study. Br J Cancer 2006, 95:1291-1295. 10.1038/sj.bjc.6603404, 2360570, 17024122.